| Revision as of 17:57, 4 March 2007 edit83.41.240.55 (talk)No edit summary← Previous edit | Revision as of 20:16, 11 March 2007 edit undoArcadian (talk | contribs)163,050 edits {{Antidepressants}}, added reference, templated existing refNext edit → | ||
| Line 1: | Line 1: | ||
| '''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s. They are thought to act by ] autoreceptor and heteroreceptor antagonism combined with specific ] antagonism. This results in increases in both noradrenergic and specific serotonergic transmission. | '''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s.<ref>{{cite journal |author=Kent J |title=SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression |journal=Lancet |volume=355 |issue=9207 |pages=911-8 |year=2000 |pmid=10752718}}</ref> They are thought to act by ] autoreceptor and heteroreceptor antagonism combined with specific ] antagonism. This results in increases in both noradrenergic and specific serotonergic transmission. | ||
| Examples of NaSSAs include: | Examples of NaSSAs include: | ||
| Line 5: | Line 5: | ||
| * ] (Remeron®, Zispin®, Avanza®, Norset®, Remergil®) | * ] (Remeron®, Zispin®, Avanza®, Norset®, Remergil®) | ||
| NaSSAs are said to have fewer side effects than ]s and ]s (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with |
NaSSAs are said to have fewer side effects than ]s and ]s (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.<ref>{{cite journal |author=Fawcett J, Barkin R |title=Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression |journal=J Affect Disord |volume=51 |issue=3 |pages=267-85 |year=1998 |pmid=10333982}} </ref> | ||
| ==See also== | ==See also== | ||
| Line 11: | Line 11: | ||
| * ] | * ] | ||
| ==References== | |||
| == External links == | |||
| <references/> | |||
| * | |||
| ] | ] | ||
| Line 20: | Line 19: | ||
| {{treatment-stub}} |
{{treatment-stub}} | ||
| {{Antidepressants}} | |||
Revision as of 20:16, 11 March 2007
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.
See also
References
- Kent J (2000). "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression". Lancet. 355 (9207): 911–8. PMID 10752718.
- Fawcett J, Barkin R (1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". J Affect Disord. 51 (3): 267–85. PMID 10333982. link
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |